Tocilizumab in Severe Covid-19 Infection, Early Experiences at a Community Hospital
Alwyn Rapose1*, Raul Davaro2 The COVID-19 global pandemic has resulted in more than 118 million cases and more than 2.5 million deaths. Most fatalities are related to severe pulmonary disease caused by a severe inflammatory response to the virus in the lungs. As yet there is no uniformly successful therapeutic agent. Tocilizumab is a monoclonal


















